Teva Pharmaceutical Industries (TEVA) Deferred Taxes (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Deferred Taxes across 10 years of filings, most recently posting -$22.0 million for Q1 2026.

• Quarterly Deferred Taxes fell 178.57% year-over-year to -$22.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$721.0 million (down 72.9% YoY) and the FY2025 annual result came in at -$671.0 million, down 5.84% from the prior year.
• Deferred Taxes rose to -$22.0 million in Q1 2026, from -$595.0 million in the prior quarter.
• Over five years, Deferred Taxes peaked at $150.0 million in Q4 2022 and troughed at -$1.1 billion in Q2 2022.
• A 5-year average of -$159.3 million and a median of -$53.0 million in 2024 frame the typical range for Deferred Taxes.
• Biggest YoY gain for Deferred Taxes was 450.0% in 2022; the steepest drop was 6868.75% in 2022.
• Tracing TEVA's Deferred Taxes over 5 years: stood at $150.0 million in 2022, then sank by 78.67% to $32.0 million in 2023, then changed by 0.0% to $32.0 million in 2024, then tumbled by 1959.38% to -$595.0 million in 2025, then soared by 96.3% to -$22.0 million in 2026.
• Business Quant data shows TEVA's Deferred Taxes at -$22.0 million in Q1 2026, -$595.0 million in Q4 2025, and $107.0 million in Q3 2025.